AdultPediatricGeriatricDosage Forms & Strengths tablet, film coated (generic) 2.5mg 5mg 10mg 20mg Erectile Dysfunction 10 mg PO ~1 hour before sexual activity; may be increased to 20 mg or reduced to 5 mg, depending on effectiveness and tolerance; not to exceed 1 dose/day Dosage Modifications Coadministration of nitrates or guanylate cyclase (GC) stimulators Contraindicated Coadministration with CYP3A4 inhibitors Tablet Ketoconazole 200 mg/day or itraconazole 200 mg/day: Vardenafil dosage not to exceed 5 mg/day Indinavir, saquinavir, atazanavir, clarithromycin, ketoconazole 400 mg/day or itraconazole 400 mg/day: Vardenafil dosage not to exceed 2.5 mg/day Ritonavir (600 mg q12hr) or cobicistat: Vardenafil dosage not to exceed 2.5 mg/72 hr Erythromycin 500 mg q8hr: Vardenafil dosage not to exceed 5 mg/day Oral disintegrating tablet (ODT) Strong or moderate CYP3A4 inhibitors: Do not use (unable to adjust vardenafil dose) Coadministration with alpha blocker Only initiate vardenafil if stabilized on alpha-blocker Stabilized on alpha-blocker therapy (eg, alfuzosin, terazosin, tamsulosin): 5 mg/day PO initially Stabilized on alpha-blocker therapy and taking moderate-to-strong CYP3A4 inhibitor: 2.5 mg/day PO initially Consider time interval between dosing when vardenafil is concomitantly used with alpha-blocker therapy Renal impairment Mild-to-severe: No dosage adjustment necessary Hemodialysis: Not recommended Hepatic impairment (tablet) Mild (Child-Pugh A): No dosage adjustment necessary Moderate (Child-Pugh B): Start 5mg PO ~1 hr before sexual activity; not to exceed 10 mg once daily Severe (Child-Pugh C): Do not use Hepatic impairment (ODT) Mild (Child-Pugh A): No dosage adjustment necessary Moderate-to-severe (Child-Pugh B or C): Do not use Pulmonary Arterial Hypertension (Orphan) Orphan designation for treatment of pulmonary arterial hypertension Orphan sponsor Respira Therapeutics, Inc; 5901 Indian School Road NE, suite 107; Albuquerque, New Mexico 87110 Not indicatedErectile Dysfunction <65 years Film-coated tablet: 10 mg PO ~1 hour before sexual activity; may be increased to 20 mg or reduced to 5 mg, depending on effectiveness and tolerance; not to exceed 1 dose/day Orally disintegrating tablet (ODT): 10 mg PO placed on tongue ~1 hour before sexual activity; not to exceed 1 dose/day; not interchangeable with 10-mg film-coated tablet; if higher or lower doses required, film-coated tablet should be prescribed >65 years Consinder 5 mg starting dose AUC and Cmax increased by 39% and 21%, respectively, in elderly men (compared with men <45 years)Interaction CheckerEnter a drug name and vardenafilNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (12)isosorbide dinitrateisosorbide dinitrate, vardenafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension.isosorbide mononitrateisosorbide mononitrate, vardenafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension.lefamulinlefamulin will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval.nitroglycerin IVnitroglycerin IV, vardenafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension.nitroglycerin POnitroglycerin PO, vardenafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension.nitroglycerin rectalvardenafil increases effects of nitroglycerin rectal by additive vasodilation. Contraindicated. Use of nitroglycerin within a few days of PDE5 inhibitors is contraindicated. PDE5 inhibitors have been shown to potentiate the hypotensive effects of organic nitrates.nitroglycerin sublingualnitroglycerin sublingual, vardenafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension.nitroglycerin topicalnitroglycerin topical, vardenafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension.nitroglycerin transdermalnitroglycerin transdermal, vardenafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension.nitroglycerin translingualnitroglycerin translingual, vardenafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension.riociguatvardenafil, riociguat. Either increases effects of the other by additive vasodilation. Contraindicated. Coadministration of PDE-5 inhibitors (eg, avanafil, sildenafil, tadalafil, vardenafil) and guanylate cyclase stimulators (eg, riociguat) is contraindicated due to risk of additive hypotension.vericiguatvardenafil, vericiguat. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Coadministration of vericiguat with PDE-5 inhibitors may result in additive hypotensive effects.Serious - Use Alternative (56)adagrasibadagrasib, vardenafil. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.alfuzosinvardenafil increases effects of alfuzosin by pharmacodynamic synergism. Contraindicated. Risk of hypotension.amisulprideamisulpride and vardenafil both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.amyl nitriteamyl nitrite, vardenafil. Mechanism: additive vasodilation. Avoid or Use Alternate Drug. Potentially fatal hypotension.anagrelideanagrelide and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.apalutamideapalutamide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.artemetherartemether and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.asenapineasenapine and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.asenapine transdermalasenapine transdermal and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.avanafilvardenafil, avanafil. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid combination; duplicate therapy is not recommended.buprenorphinebuprenorphine and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine buccalbuprenorphine buccal and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine subdermal implantbuprenorphine subdermal implant and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine transdermalbuprenorphine transdermal and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine, long-acting injectionbuprenorphine, long-acting injection and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.carbamazepinecarbamazepine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.ceritinibceritinib and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.clarithromycinclarithromycin and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.crizotinibcrizotinib and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.desfluranedesflurane and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.doxazosinvardenafil increases effects of doxazosin by pharmacodynamic synergism. Contraindicated. Risk of hypotension.encorafenibencorafenib and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.entrectinibentrectinib and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.eribulineribulin and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.fexinidazolefexinidazole and vardenafil both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval.glyceryl trinitrate prglyceryl trinitrate pr, vardenafil. Mechanism: additive vasodilation. Avoid or Use Alternate Drug. Potentially fatal hypotension.hydroxychloroquine sulfatehydroxychloroquine sulfate and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.idelalisibidelalisib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substratesisofluraneisoflurane and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.itraconazoleitraconazole and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.ivosidenibivosidenib and vardenafil both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.ivosidenib will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternative therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.macimorelinmacimorelin and vardenafil both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.mefloquinemefloquine increases toxicity of vardenafil by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.mobocertinibmobocertinib and vardenafil both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently.moxisylytevardenafil increases effects of moxisylyte by pharmacodynamic synergism. Contraindicated. Risk of hypotension.nicorandilnicorandil, vardenafil. Mechanism: additive vasodilation. Avoid or Use Alternate Drug. Potentially fatal hypotension.ondansetronondansetron and vardenafil both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.oxaliplatinoxaliplatin and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.phenoxybenzaminevardenafil increases effects of phenoxybenzamine by pharmacodynamic synergism. Contraindicated. Risk of hypotension.phentolaminevardenafil increases effects of phentolamine by pharmacodynamic synergism. Contraindicated. Risk of hypotension.prazosinvardenafil increases effects of prazosin by pharmacodynamic synergism. Contraindicated. Risk of hypotension.ribociclibribociclib increases toxicity of vardenafil by QTc interval. Avoid or Use Alternate Drug.rifabutinrifabutin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.rifampinrifampin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.sevofluranesevoflurane and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.silodosinvardenafil increases effects of silodosin by pharmacodynamic synergism. Contraindicated. Risk of hypotension.siponimodsiponimod and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.St John's WortSt John's Wort will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.terazosinvardenafil increases effects of terazosin by pharmacodynamic synergism. Contraindicated. Risk of hypotension.tetrabenazinetetrabenazine and vardenafil both increase QTc interval. Avoid or Use Alternate Drug.tucatinibtucatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling.umeclidinium bromide/vilanterol inhaledvardenafil increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.vemurafenibvemurafenib and vardenafil both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.vilanterol/fluticasone furoate inhaledvardenafil increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.voxelotorvoxelotor will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.zotepinevardenafil increases effects of zotepine by pharmacodynamic synergism. Contraindicated. Risk of hypotension.Monitor Closely (164)adagrasibadagrasib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors albuterolalbuterol and vardenafil both increase QTc interval. Use Caution/Monitor.alfuzosinvardenafil and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and vardenafil both increase QTc interval. Use Caution/Monitor.amifostineamifostine, vardenafil. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Monitor blood pressure response to phosphodiesterase type 5 (PDE5) inhibitors in patients receiving concurrent blood pressure lowering therapy.amiodaroneamiodarone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors amobarbitalamobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.apomorphineapomorphine and vardenafil both increase QTc interval. Use Caution/Monitor.aprepitantaprepitant will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors arformoterolarformoterol and vardenafil both increase QTc interval. Use Caution/Monitor.aripiprazolearipiprazole and vardenafil both increase QTc interval. Use Caution/Monitor.armodafinilarmodafinil will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.artemether/lumefantrineartemether/lumefantrine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.asenapinevardenafil increases effects of asenapine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Risk of hypotension.atazanaviratazanavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Limit vardenafil dose to 2.5 mg/24 hratomoxetineatomoxetine and vardenafil both increase QTc interval. Use Caution/Monitor.bedaquilinevardenafil and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closelybenazeprilvardenafil, benazepril. Either increases effects of the other by Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.bicalutamidebicalutamide will increase the level or effect of vardenafil by affecting